Patient O.T. is a 26-year-old white woman who works in the music industry. She was diagnosed with pneumonia and treated with inhalers. Shortly afterward, she developed spells of tachycardia. Her episodes of tachycardia were primarily associated with upright posture. In addition to rapid palpitations, she complained of lightheadedness and presyncope on standing, intermittent stabbing chest pains (typically on standing), mental clouding with an inability to concentrate, severe fatigue, and exercise intolerance. Orthostatic vital signs recorded a supine heart rate (HR) of 73 bpm with a blood pressure (BP) of 103/72 mm Hg. After standing for 1 minute, her HR increased to 106 bpm with a BP of 109/80 mm Hg, and after 5 minutes, her HR was 122 bpm with a BP of 118/75 mm Hg. She was diagnosed with postural tachycardia syndrome (POTS).

Upright Posture
Under normal conditions, the assumption of upright posture affects an instantaneous shift of ≈500 mL of blood from the thorax to the lower abdomen, buttocks, and legs. There is a secondary shift of plasma volume (10% to 25%) out of the vasculature and into the interstitial tissue, which decreases venous return to the heart (preload), resulting in a transient decline in cardiac filling and BP. This unloads the baroreceptors and triggers a compensatory decrease in parasympathetic tone and an increase in sympathetic activation, with a resultant increase in HR and systemic vasoconstriction (countering the initial decline in BP). The net hemodynamic effect of transition to upright posture is a 10- to 20-bpm increase in HR, a negligible change in systolic BP, and a ≈5-mm Hg increase in diastolic BP. Orthostatic dysregulation occurs when this gravitational regulatory mechanism does not respond properly. Patients can present with orthostatic hypotension (seen in autonomic nervous system failure) or with orthostatic tachycardia (seen in POTS). Patients with POTS typically maintain (or even increase) their BP on standing. The cardinal hemodynamic feature in POTS is that HR increases excessively and is associated with multiple symptoms on standing that improve with recumbence.

Diagnostic Criteria and Common Clinical Features of POTS
POTS is defined (Table 1) as the presence of chronic symptoms of orthostatic intolerance (at least 6 months) accompanied by an increased HR ≥30 bpm within 10 minutes of assuming an upright posture and in the absence of orthostatic hypotension (a decrease in BP >20/10 mm Hg).1 An example of a tilt test in a POTS patient is shown in Figure 1. In young children, a higher HR threshold (≥40 bpm) should be used because healthy younger children have a greater orthostatic tachycardia.2 There is significant diurnal variability in the magnitude of orthostatic tachycardia; therefore, postural vital signs should be performed in the morning to optimize diagnostic sensitivity for POTS. The orthostatic tachycardia must occur in the absence of other overt causes of orthostatic tachycardia such as prolonged bed rest, medications that impair autonomic regulation (such as vasodilators, diuretics, antidepressants, or anxiolytic agents), or chronic debilitating disorders that might cause tachycardia (such as dehydration, anemia, or hyperthyroidism).

Symptoms often include both cardiac symptoms (rapid palpitations, lightheadedness, chest discomfort, and dyspnea) and noncardiac symptoms (mental clouding [“brain fog”], headache, nausea, tremulousness, blurred or tunneled vision, poor sleep, exercise intolerance, and fatigue). Even activities of daily living such as bathing or doing housework may greatly exacerbate symptoms, with resultant fatigue. This can pose significant limitations on functional capacity. Although presyncope and lightheadedness are common in these patients, only a minority (∼30%) actually faint. The chest pains are almost never attributable to coronary artery obstruction but may
Patients frequently report to 85% of child-bearing age (13–50 years).4 Patients frequently report that their symptoms began after acute stressors such as pregnancy, major surgery, or a presumed viral illness, but in others cases, symptoms develop more insidiously. About 80% of female patients report an exacerbation of symptoms around menstruation.5 Many patients have been codiagnosed with irritable bowel syndrome; some have hypermobile joints; and some have abnormal sudomotor regulation.

A striking physical feature in ≈50% of patients with POTS is a dependent acrocyanosis (Figure 2). These patients experience a dark red-blue discoloration of their legs (feet to above knees), which are cold to the touch. The reasons underlying this phenomenon are not clear but may relate to abnormalities in nitric oxide activity in the skin of POTS patients.6

**Psychological Profile in POTS**

Patients with POTS are sometimes clinically diagnosed as having anxiety disorders such as panic disorder. When assessed with a structured evaluation for Diagnostic and Statistical Manual (fourth edition, text revision) criteria, POTS patients did not have a higher incidence of major depressive disorder, anxiety disorders, or substance abuse than the general population.7

When assessed with the Beck Anxiety Inventory, patients reported elevated anxiety scores (23±10 versus 7±8; P<0.001).7 However, the Beck Anxiety Inventory scores both somatic anxiety and psychological symptoms, which is a problem because somatic symptoms may overlap with hyperadrenergic states (as seen in POTS). When POTS patients were assessed with a psychological-based measure of anxiety (Anxiety Sensitivity Index), there was a trend toward less anxiety in the patients than in the general population (15±10 versus 19±9; P=0.063).7 It is possible that some of the anxiety attributed to patients with POTS might be a result of a misinterpretation of their physical symptoms.

Many POTS patients complain of memory problems. In formal testing with the inattention score from the Connors adult attention-deficit/hyperactivity disorder rating scale, POTS patients scored significantly worse than healthy control subjects.7 This suggests that the problem in POTS may not be with memory per se but with diminished attention.

**Fatigue, Sleep Problems, and Quality of Life in POTS**

POTS patients commonly complain of fatigue, unrefreshing sleep, and daytime sleepiness. When formally assessed with the Fatigue Visual Analog Scale, the Medical Outcomes Study Sleep Survey, and the Epworth Sleepiness Scale, POTS patients had more sleep problems (Sleep Problems Index: 58±18 versus 20±13; P<0.0001) and excessive daytime sleepiness (10.2±5.7 versus 6.2±3.2; P<0.0001) compared with healthy control subjects.5 POTS patients also had higher fatigue levels (7.5±2.0 versus 2.8±2.5; P<0.0001). We8 and others9 have documented low health-related quality of life in patients with POTS. Using the Short Form-36, Benrud-Larssen et al9 reported that physical and mental composite scores for POTS patients were comparable to those for patients with congestive heart failure. It is noteworthy that of the 8 domains specifically addressed by the Short Form-36, the only domain in which POTS patients did not fare worse than the control group was mental health.9

The subjects in the aforementioned sleep study also completed the RAND-36, a validated general health-related quality-of-life tool. There was a strong correlation between the RAND-36 physical health composite scores and the Sleep Problems Index (R=0.53, P<0.0001), with >50% of the variance in physical health explained by the variance in sleep quality.8

**Pathophysiology of POTS**

POTS is a syndrome and not a disease. Many disorders with the common key clinical presentation of orthostatic tachycardia have been described. Much has been learned about specific features or subtypes within POTS, although a simple test to categorize the individual

![Figure 1. Heart rate (HR) and blood pressure (BP) with upright tilt in postural tachycardia syndrome (POTS). HR, BP, and tilt table angle are shown for a representative patient with POTS (left) and for a healthy subject (right) during a 30-minute head-up tilt test. With tilt, HR immediately increases in POTS and peaks at >170 bpm before the end of the tilt, whereas the HR of the healthy subject rises to just over 100 bpm. BP was largely unchanged in the POTS patient. Figure reprinted with permission from Raj SR. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006;6:84–99.1]
patient remains elusive. Some common POTS phenotypes are described here.

Neuropathic POTS
Although many POTS patients have high plasma norepinephrine levels, it would seem paradoxical that an autonomic neuropathy is proposed as an underlying process. Yet some patients have a form of dysautonomia, with preferential denervation of sympathetic nerves from the lower limbs. Jacob et al.10 showed that some patients with POTS had less norepinephrine release (less sympathetic activation) in their lower extremities.

Central Hyperadrenergic POTS
Many patients with POTS have elevated levels of plasma norepinephrine, suggestive of a hyperadrenergic state. This is most commonly secondary to a partial dysautonomia or hypovolemia. In a small subgroup of patients, the primary underlying problem seems to be excessive sympathetic discharge. These patients often have extremely high levels of upright plasma norepinephrine (>1000 pg/mL and occasionally >2000 pg/mL, with an upper limit of normal of 475 pg/mL in our clinical laboratory). Plasma metanephrines will exclude a pheochromocytoma. This subgroup of patients sometimes have large increases in BP on standing, indicating that baroreflex buffering is somehow impaired. Therapy in these patients targets a decrease in sympathetic tone both centrally and peripherally. Central sympatholytics such as methyldopa or clonidine may be used. Peripheral β-adrenergic blockade may be better tolerated by these patients than by those with primary hypovolemia.

Norepinephrine Transporter Deficiency and Blockers
A specific genetic abnormality has been identified in a kindred with hyperadrenergic POTS.11 These individuals have a single point mutation causing loss of function in the norepinephrine transporter. The resultant diminished norepinephrine clearance leads to a hyperadrenergic state in response sympathetic nerve activation.

Although functional norepinephrine transporter mutations might be infrequent, many antidepressant and attention deficit medications work at least in part through inhibition of norepinephrine transporter. This includes traditional drugs such as tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (eg, duloxetine, venlafaxine, or milnacipran), or purer norepinephrine transporter inhibitors (eg, atomoxetine or reboxetine). Pharmacological norepinephrine transporter inhibition can recreate an orthostatic tachycardia phenotype in susceptible healthy volunteer subjects.12 POTS patients might have less tachycardia reserve and be more susceptible to exaggerated tachycardia with these medications.

Mast Cell Activation
Some patients with POTS present with episodic flushing associated with surges in tachycardia and have coexistent mast cell activation. They may have abnormal increases in urine methylhistamine (the primary urinary metabolite of histamine),13 which should ideally be measured from a 4-hour sample at the time of a flushing episode (not a 24-hour sample). This can be associated with dyspnea, headache, lightheadedness, excessive diuresis, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. These patients often have a hyperadrenergic response to posture, with both orthostatic tachycardia and hypertension. There are many triggers for the flushing, including prolonged standing, exercise, premenstrual cycle, meals, and sexual intercourse.

Centrally acting agents to decrease the sympathetic nervous system discharge (eg, methyldopa or clonidine) may prove effective, although β-blockers may actually trigger mast cell degranulation and worsen symptoms. Treatment can also target mast cell mediators, with a combination of antihistamines (H1 and H2 antagonists) and possible use of nonsteroidal agents in refractory cases.

Hypovolemia and Blood Volume Regulation
Many, but not all, patients with POTS have low blood volumes.14 Using the 131I-labeled human serum albumin method, we found that POTS patients had a plasma volume deficit of almost 13%.14 The renin-angiotensin-aldosterone system plays a key role in the neurohormonal regulation of plasma volume in humans. Plasma renin activity and
angiotensin II would be expected to increase in response to hypovolemia to promote blood volume expansion. Angiotensin II promotes sodium and water retention indirectly by stimulating aldosterone secretion.

Patients with orthostatic tachycardia who were also hypovolemic have inappropriately low levels of standing plasma renin activity and aldosterone compared with normovolemic subjects. One would have expected a compensatory increase in both plasma renin activity and aldosterone resulting from the hypovolemia in these patients, and these low levels are a paradox that remains unexplained.

More recently, we have reported high levels of angiotensin II levels circulating in POTS patients without a commensurate increase in angiotensin(1–7), suggesting that POTS patients might have decreased angiotensin II metabolism. The aldosterone level is lower per unit of angiotensin II in POTS patients. These data suggest that abnormalities in the renin-angiotensin-aldosterone axis might have a role in the pathophysiology of POTS by contributing to hypovolemia and impaired sodium retention.

**Investigation of POTS**

The evaluation of a patient with POTS starts with a detailed history and physical examination. POTS can be confused with pheochromocytoma because of the paroxysms of hyperadrenergic symptoms (eg, palpitations and lightheadedness). Patients with pheochromocytoma are more likely to have these symptoms while lying down than POTS patients. The diagnosis of pheochromocytoma is made by assessment of plasma or urinary metanephrines. We order a complete blood count and an electrolyte panel to exclude severe anemia or gross electrolyte disturbances. Some physicians specializing in POTS will also assess vitamin B12 levels, iron indexes, and serological markers for celiac disease, although there are insufficient data supporting the routine use of these tests.

The tachycardia in POTS patients should originate from the sinus node. An ECG should be routinely performed to exclude the presence of an accessory bypass tract or other abnormalities of cardiac conduction. A Holter monitor might prove useful to exclude a reentrant tachyarrhythmia, especially if the tachycardia is paroxysmal with a sudden onset and offset. The physician must determine that cardiac left ventricular function is normal, using an echocardiogram if needed. Peripartum cardiomyopathy, for example, can present in a manner similar to POTS.

We often measure plasma norepinephrine levels in both a supine and a standing position (at least 10 minutes in each position before blood sampling). The supine norepinephrine is often within the normal range in POTS patients, whereas the upright norepinephrine is frequently elevated (>600 pg/mL), reflecting the exaggerated neural sympathetic tone present in these patients while upright.

Autonomic reflexes are usually intact on formal tests of autonomic nervous system function. POTS patients often have preserved vagal function (as reflected by their sinus arrhythmia ratio in response to deep breathing) and a vigorous pressor response to the Valsalva maneuver, with an exaggerated BP recovery and overshoot both before and after release. Given the complaints of exercise intolerance, formal cardiopulmonary exercise testing can be useful for objective documentation of exercise capacity; it can also be used serially to quantify functional capacity over time.

The blood volume is low in many patients with POTS. This can be objectively assessed with nuclear medicine tests to directly measure either the plasma volume or the red cell volume. Some patients with POTS have coexistent complaints of episodic flushing, and a minority of these cases result from an associated mast cell activation disorder. This can be diagnosed by measuring methylhistamine levels from a 4-hour urine sample immediately after a severe flushing spell.

**Nonpharmacological Treatment of POTS**

No therapy is uniformly successful, and combinations of approaches are often needed. Efforts should initially focus on treating any reversible causes. If a patient has had a bout of prolonged bed rest, his or her symptoms should gradually improve as the patient readjusts to upright posture. Treatment should be optimized for any chronic disease that is present. Radiofrequency ablation may be needed to treat reentrant supraventricular tachyarrhythmia, but radiofrequency sinus node modification for the sinus tachycardia of POTS is not recommended because it often makes the patient’s symptoms worse (and occasionally pacemaker dependent). Specific therapies are summarized in Table 2.

Patient education is important. Patients with POTS should avoid aggravating factors such as dehydration and extreme heat. To ensure adequate hydration, we ask our patients to consume 8 to 10 cups of water daily and to increase their sodium intake to up to 8 to 10 g/d. If this cannot be accomplished with dietary modification, supplemental NaCl tablets (with meals) can be used. Elastic support hose can help to minimize the degree of peripheral venous pooling and to enhance venous return. We recommend panty hose (waist high)–style stockings with 30 to 40 mmHg of pressure.

Acute blood volume expansion will over the short-term improve symptoms and control HR. Jacob et al found that 1 L of normal saline infused intravenously over 1 hour normalized the orthostatic tachycardia (before, 33±5 bpm; after, 15±3 bpm). Acutely, this treatment is more effective at HR control than other medications. Although this can be a very effective emergency therapy, it is not a practical day-to-day approach.
Exercise
Exercise has routinely been recommended as part of the treatment regimen for many years. Unfortunately, POTS patients report feeling debilitated for days after exertion, limiting compliance. Anecdotally, patients who exercise seem to have a better long-term prognosis, but it is not certain if this is a result of the exercise or of their ability to exercise. Fu et al recently administered a structured 3-month exercise program to 19 patients with POTS. This relatively short intervention reduced orthostatic tachycardia and improved quality of life. Physiological parameters such as blood volume, stroke volume, and left ventricular mass all improved over the 3 months. This study elegantly showed that exercise, not just the ability to exercise, is important in this population.

Pharmacological Treatment of POTS
The Food and Drug Administration has not approved any medications for the treatment of POTS. Therefore, all agents used for this disorder are off label. Furthermore, all trials have been of a short duration, with none tested in a long-term, properly powered, randomized, clinical trial.

The initial pharmacological approach is to withdraw medications that might be predisposing to tachycardia (such as diuretics, vasodilators, and norepinephrine transporter blockers). Given their demographics, many POTS patients take oral contraceptives. Some agents (eg, Yaz or Yasmin) include drospirenone as the progestin, which is a spironolactone analog. Given that inappropriately low aldosterone and low blood volume have been identified as a problem in some POTS patients, we recommend that patients be switched to an oral contraceptive that uses a different progestin.

In patients in whom the presence of hypovolemia is either known or strongly suspected, fludrocortisone (aldosterone analog) is often used. Through enhanced sodium retention, it should expand the plasma volume. Adverse effects can include hypokalemia, worsening headaches, acne, and fluid retention with edema. Another volume-expanding agent that may be helpful for short-term use is desmopressin (DDAVP). This agent causes the kidney to retain free water but not sodium. Potential side effects include hyponatremia with regular use.

Pharmacological Treatment of POTS

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise program</td>
<td>Primarily aerobic with some leg-based resistance exercises</td>
</tr>
<tr>
<td></td>
<td>Initially avoid upright exercises and focus on rowing machines, swimming,</td>
</tr>
<tr>
<td></td>
<td>and recumbent cycles</td>
</tr>
<tr>
<td>Augment blood volume/venous return</td>
<td></td>
</tr>
<tr>
<td>Increase NaCl intake by diet or tablets</td>
<td>Target, 8–10 g/d; can add in NaCl 1-g tablets as needed</td>
</tr>
<tr>
<td>Increase NaCl intake by diet or tablets</td>
<td>Target, 8–10 g/d; can add in NaCl 1-g tablets as needed</td>
</tr>
<tr>
<td>Panty hose–style compression stockings</td>
<td>30–40 mmHg counterpressure</td>
</tr>
<tr>
<td>Withdraw OCP with drospirenone</td>
<td>Drospirenone is a spironolactone analog that could worsen hypovolemia</td>
</tr>
<tr>
<td>Fludrocortisone</td>
<td>0.1–0.2 mg/d orally; watch for hypokalemia</td>
</tr>
<tr>
<td>Desmopressin (DDAVP)</td>
<td>0.2 mg orally 1 time for occasional use</td>
</tr>
<tr>
<td></td>
<td>Could cause hyponatremia with regular use</td>
</tr>
<tr>
<td>Hemodynamic agents</td>
<td></td>
</tr>
<tr>
<td>Withdraw drugs that block the norepinephrine transporter</td>
<td>These drugs can increase peripheral sympathetic tone and worsen tachycardia</td>
</tr>
<tr>
<td></td>
<td>These include tricyclic antidepressants, ADHD drugs, and SNRI antidepressants</td>
</tr>
<tr>
<td>Propranolol</td>
<td>10–20 mg orally 3–4 times a day</td>
</tr>
<tr>
<td></td>
<td>Low doses to take the edge off of tachycardia are more effective than higher doses</td>
</tr>
<tr>
<td>Pyridostigmine</td>
<td>30–60 mg orally 3 times a day</td>
</tr>
<tr>
<td></td>
<td>May increase parasympathetic tone for augmented HR control</td>
</tr>
<tr>
<td></td>
<td>Can increase GI motility, which can be major source of intolerance</td>
</tr>
<tr>
<td>Midodrine</td>
<td>5–10 mg orally every 4 h in 3 doses (not close to bedtime)</td>
</tr>
<tr>
<td></td>
<td>Side effects include goose bumps, scalp itch, hypertension and urinary retention</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Modafinil</td>
<td>100 mg orally twice a day</td>
</tr>
<tr>
<td></td>
<td>Approved for various sleep problems but may help with mental alertness and concentration in patients</td>
</tr>
</tbody>
</table>

ADHD indicates attention deficit/hyperactivity disorder; GI, gastrointestinal; NaCl, table salt; OCP, oral contraceptive pill; and SNRI, serotonin-norepinephrine reuptake inhibitor.
been concerned about the risk of hypovolemia in patients told to drink free water copiously.

Midodrine is a peripheral α-1 agonist that serves as a vasoconstrictor. It might be most useful in patients with neuropathic POTS, which can be associated with a failure of vascular resistance. Jacob et al16 have documented that midodrine reduces orthostatic tachycardia, but this effect is more modest than that of intravenous saline. Midodrine can cause goose bumps, scalp tingling, or headaches, which can limit its tolerability.

β-Adrenergic blockers are commonly used in cardiology clinics to control tachycardia. Many patients with POTS, however, complain of excessive fatigue or intolerance to β-blockers. Reducing the HR in POTS would be counterproductive if the increase in HR were purely compensatory for another physiological shortfall (eg, low stroke volume) but could be useful if the tachycardia were overcompensation for the physiological stimuli. We have found low-dose short-acting propranolol (10–20 mg orally) to be very effective at lowering standing HR and improving symptoms in POTS patients.19 More complete β-blockade, however, is less well tolerated.19

Pyridostigmine is a peripheral acetylcholinesterase inhibitor that can increase the levels of synaptic acetylcholine at both the autonomic ganglia and peripheral muscarinic parasympathetic receptors. Pyridostigmine 30 to 60 mg orally 3 times a day has been reported to result in long-term symptom improvement in ≈50% of POTS patients.20 Pyridostigmine can enhance bowel motility; thus, gastrointestinal adverse events are the most common reason for discontinuation of the drug.20

Central sympatholytic agents can be useful in patients with the central hyperadrenergic form of POTS but may not be as well tolerated in patients with neuropathic POTS. Clonidine is an α-2 agonist that acts centrally to decrease sympathetic nervous system outflow. Clonidine 0.1 to 0.2 mg orally 2 to 3 times a day (eventually switched to a long-acting patch) can stabilize HR and BP in patients with high sympathetic nervous system activity. Methyldopa 125 to 250 mg orally 2 times a day is a false neurotransmitter that is sometimes better tolerated because of its longer half-life. Unfortunately, both drugs can cause drowsiness and fatigue and worsen the mental clouding of some patients.

Many patients are also greatly troubled by mental clouding or trouble concentrating. Modafinil, a stimulant with a mechanism that is not yet clear, can improve alertness in some patients with POTS. Caution is advised, however, because modafinil may aggravate the orthostatic tachycardia.

Conclusions

POTS is a disorder of the autonomic nervous system that can produce substantial disability among previously healthy people. Patients with POTS demonstrate an HR increase of ≥30 bpm within 10 minutes of standing (or higher in children), are often hyperadrenergic, and tend to have a low blood volume. Therapies targeting the hypovolemia and the excess sympathetic nervous system activation may help relieve symptoms.

Epilogue

Patient O.T. was intolerant to both midodrine (“felt like I had bugs in my hair”) and fludrocortisone (marked bloating). She was not able to increase her dietary salt intake, so she took NaCl tablets 1 g orally 3 times a day. She used waist-high compression stockings and reported significant improvement in her symptoms with propranolol 20 mg orally 3 times a day. Her vitamin B₁₂ level was low, and this was supplemented. She discontinued her oral birth control containing drospirenone and switched to an agent with a different progestin. Finally, she used DDAVP 0.2 mg orally occasionally for improved orthostatic tolerance for special events. This combination of therapies helped to improve her orthostatic tolerance, but she was not able to continue to work because of her brain fog.

Acknowledgments

I thank David Robertson, MD, for his thoughtful review of this manuscript.

Sources of Funding

This work was supported in part by National Institutes of Health grants P01 HL56793, R01 HL102387, and UL1 TR000445.

Disclosures

None.

References

11. Shannon JR, Flattner NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD,


Postural Tachycardia Syndrome (POTS)
Satish R. Raj

Circulation. 2013;127:2336-2342
doi: 10.1161/CIRCULATIONAHA.112.144501
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/127/23/2336

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/